Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Face it. It's absolutely over for this company.

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Oct 12, 2021 12:26pm

105 Views

Post# 33997616

RE:Face it. It's absolutely over for this company.

losingmyshirt wrote: Too many legitimate companies around the globe are miles ahead of Kalytera and their pipe dream.

Poor Bob Farrell. he was only doing what his maters tasked him with.

Blame yourselves for being gullible.

Have a great day.

TicToc

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand